Publications & Media

The latest news in technology and science from Protagenic

Protagenic Papers

November 29, 2022

Skeletal muscle metabolism and contraction performance regulation by teneurin C-terminal-associated peptide-1

November 26, 2022

Distal extracellular teneurin region (teneurin C-terminal associated peptide; TCAP) possesses independent intracellular calcium regulating actions, in vitro: A potential antagonist of corticotropin-releasing factor (CRF)

May 02, 2022

Role of Teneurin C-Terminal Associated Peptides (TCAP) on Intercellular Adhesion and Communication

January 11, 2021

Teneurin C-Terminal Associated Peptide (TCAP)-3 Increases Metabolic Activity in Zebrafish

August 07 2020

Information Processing in Affective Disorders: Did an Ancient Peptide Regulating Intercellular Metabolism Become Co-Opted for Noxious Stress Sensing?

12 November 2019

Synthetic Peptides as Therapeutic Agents: Lessons Learned From Evolutionary Ancient Peptides and Their Transit Across Blood-Brain Barriers

July 31, 2019

Activity of the carboxy terminal peptide region of the teneurins and its role in neuronal function and behaviour in mammals. In Origins of Neuropathology: The Significance of Teneurin-Latrophilin Interaction.

June 27, 2019

A Putative Role of Teneurin-2 and Its Related Proteins in Astrocytes

February 01, 2019

Teneurin C-terminal associated peptide (TCAP)-1 and latrophilin interaction in HEK293 cells: Evidence for modulation for intercellular adhesion.

February 07, 2018

A novel role of the corticotropin-releasing hormone (CRH) regulating peptide, teneurin C-terminal associated peptide (TCAP)-1 on glucose uptake into the brain.

(This paper was highlighted on the cover on the journal)

September 19, 2017

Teneurin-2 presence in rat and human odontoblasts

May 26, 2017

Teneurin C-terminal associated peptide (TCAP)-1 and corticotropin-releasing factor (CRF) interactions in the modulation of cocaine-related behaviour. In 'The Neuroscience of Cocaine: Mechanisms and Treatment'.

January 21, 2015

Teneurins and Alzheimer's Disease: A Suggestive Role for a Unique Family of Proteins

April 21, 2014

Repeated Intravenous Administrations of Teneurin-c Terminal Associated Peptide (TCAP-1) Attenuates Reinstatement of Cocaine Seeking by Corticotropin-releasing Factor (CRF) in Rats

March 10, 2011

Teneurin C-terminal Associated Peptide (TCAP-1) Modulates Dendritic Morphology in Hippocampal Neurons and Decreases Anxiety-like Behaviors in Rats

September 13, 2010

Teneurin C-terminal Associated Peptide-1 Blocks the Effects of Corticotropin-releasing Factor on Reinstatement of Cocaine Seeking and on Cocaine-induced Behavioural Sensitization

December 21, 2009

Behavioral Effects of Neuropeptides in Rodent Models of Depression and Anxiety

November 12, 2009

Synthetic Peptides as Therapeutic Agents: Lessons Learned from Evolutionary Ancient Peptides and Their Transit Across Blood-Brain Barriers

November 4, 2007

Repeated Intracerebral Teneurin C-terminal Associated Peptide (TCAP-1) Injections Produce Enduring Changes in Behavioral Responses to Corticotropin-releasing Factor (CRF) in Rat Models of Anxiety

July 28, 2007

Corticotropin-releasing Factor (CRF)-induced Behaviors Are Modulated by Intravenous Administration of Teneurin C-terminal Associated Peptide-1 (TCAP-1)

February 23, 2007

Regulation of Neurite Growth in Immortalized Mouse Hypothalamic Neurons and Rat Hippocampal Primary Cultures by Teneurin C-terminal-associated Peptide-1

March 23, 2006

Bupropion-sr, Sertraline, or Venlafaxine-xr after Failure of SSRIs for Depression

Webinars

Past Webinars

Protagenic Therapeutics, Inc. (PTIX) Virtual Science Review

Protagenic Therapeutics, Inc. hosted a scientific webinar reviewing its programs designed for the treatment of patients with Depression, PTSD, Anxiety and Addiction.

The webinar features presentations by scientific founder David Lovejoy, PhD; PTI Chief Operating Officer Andrew Slee, PhD; and its Chief Medical Officer Robert Stein, MD, PhD.

Dr.David Lovejoy, PhD — events leading to the discovery of PT00114 and its subsequent evolution.
Chief Operating Officer Andrew Slee, PhD — the compelling evidence which has been generated in all relevant disease models.
Chief Medical Officer Robert Stein, MD, PhD — how PT00114 may fit in the pharmacopeia of available therapies for stress-related disorders as well as the unmet need of addiction withdrawal therapy.

In addition, the company provided an update on PT00114’s upcoming clinical program, including the structure of the anticipated Phase I/IIa multi-center clinical trial.

Protagenic Therapeutics, Inc. (PTIX) Key Opinion Leader (KOL) PT00114 Webinar

Protagenic Therapeutics, Inc.’s key opinion leader (KOL) webinar focused on PT00114 for the regulation of stress in patients with Depression, PTSD, Anxiety and Addiction.

The webinar features a presentation by KOL Dr. Maurizio Fava, Massachusetts General Hospital (MGH), who is serving as principal investigator in Protagenic’s upcoming Phase 1/2a clinical trial.

Protagenic’s management team also provided an overview of the ongoing clinical development program and potential commercial opportunity for PT00114, which is known scientifically as teneurin C-terminal associated peptide (TCAP), a naturally occurring peptide responsible for regulation of stress response in the brain.

Presentations

June 17, 2021

The HCWainwright Psychedelics Conference PTIX Presentation

Psychedelics in Psychiatry and Beyond